$Hla-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: a Multicentre Analysis$

Hla-Haploidentical Transplantation for Relapsed/Refractory Hodgkin Lymphoma: a Multicentre Analysis

Highlights • HaploSCT is a valuable alternative for HL patients relapsing after an ASCT. • In this series, 2-year PFS and OS probabilities were 54% and 66%, respectively. • This appears to be a feasible strategy for patients in middle-income countries.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Biology of blood and marrow transplantation 2017
Hauptverfasser:	Pitombeira de Lacerda, Marcelo, Arrais Rodrigues, Celso, Pereira, André Domingues, Novis, Yana, Fonseca, Marina, Silva, Roberto L, Macedo, Maria C.M.A, Hamerschlak, Nelson, Esteves, Iracema, Schmidt Filho, Jayr, Nascimento, Marina M, Rocha, Vanderson
Format:	Artikel
Sprache:	eng
Schlagworte:	Hematology, Oncology and Palliative Medicine
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • HaploSCT is a valuable alternative for HL patients relapsing after an ASCT. • In this series, 2-year PFS and OS probabilities were 54% and 66%, respectively. • This appears to be a feasible strategy for patients in middle-income countries.
ISSN:	1083-8791
DOI:	10.1016/j.bbmt.2017.01.079